NCT07730294
Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery
At risk: Primary completion moved at least 31 days later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date pushed from Oct 2026 to Nov 2026
- Primary and study completion dates: Oct 2028 to Nov 2028
- Site details revised
- Notable Start date: Aug 2026 to Oct 2026
- Eligibility criteria expanded, about 13 words
- Primary and study completion pushed from Aug 2028 to Oct 2028
- Secondary endpoints: details revised at 5 of 5 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (5)
Arms and interventions
Participants in this arm will receive low dose oxytocin beginning one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.
Participants in this arm will receive high dose oxytocin beginning one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.
Participants in this arm will receive placebo beginning one week prior to surgery, continues on the day of the surgery, and extends through the week following the surgery.
Drugs: Oxytocin (Low dose), Oxytocin (High dose), Placebo (saline)
Sites
1 site in 1 country
- Yale UniversityNew Haven, Connecticut, United States